Statins and liver toxicity: a meta-analysis (Q35783702)

10 August 2017

1 reference

title

Statins and liver toxicity: a meta-analysis (English)

1 reference

10 August 2017

1 reference

1

Simon de Denus

1 reference

10 August 2017

Sarah A Spinler

2

1 reference

10 August 2017

Kristin Miller

series ordinal

3

1 reference

10 August 2017

Andrew M Peterson

series ordinal

4

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

24

1 reference

10 August 2017

584-591

1 reference

10 August 2017

5

1 reference

New cholesterol guidelines, new treatment challenges

10 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Early statin therapy for acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Getting more people on statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

21 January 2018

The liver and lovastatin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Rhabdomyolysis and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Physicians' interpretation of "class effects": a need for thoughtful re-evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Clinically relevant differences between the statins: implications for therapeutic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Safety and statin therapy: reconsidering the risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.6.584.34738

10.1592/PHCO.24.6.584.34738

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference